ES2525215T3 - Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado - Google Patents

Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado Download PDF

Info

Publication number
ES2525215T3
ES2525215T3 ES06746833.0T ES06746833T ES2525215T3 ES 2525215 T3 ES2525215 T3 ES 2525215T3 ES 06746833 T ES06746833 T ES 06746833T ES 2525215 T3 ES2525215 T3 ES 2525215T3
Authority
ES
Spain
Prior art keywords
chiral
optionally substituted
brs
nmr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06746833.0T
Other languages
English (en)
Spanish (es)
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of ES2525215T3 publication Critical patent/ES2525215T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06746833.0T 2005-05-25 2006-05-25 Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado Expired - Lifetime ES2525215T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005151864 2005-05-25
JP2006065762 2006-03-10
JP2006065762 2006-03-10
WOPCT/JP2006/310231 2006-05-23
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
PCT/JP2006/310454 WO2006126637A1 (ja) 2005-05-25 2006-05-25 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (1)

Publication Number Publication Date
ES2525215T3 true ES2525215T3 (es) 2014-12-19

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06746833.0T Expired - Lifetime ES2525215T3 (es) 2005-05-25 2006-05-25 Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado

Country Status (20)

Country Link
US (4) US8084460B2 (enExample)
EP (1) EP1889848B8 (enExample)
JP (1) JP4323547B2 (enExample)
KR (1) KR100912782B1 (enExample)
CN (1) CN101228172B (enExample)
AU (1) AU2006250390B2 (enExample)
BE (1) BE2019C533I2 (enExample)
BR (1) BRPI0610343B8 (enExample)
CA (1) CA2609733C (enExample)
DK (1) DK1889848T3 (enExample)
ES (1) ES2525215T3 (enExample)
FR (1) FR19C1042I2 (enExample)
HU (1) HUS1900034I1 (enExample)
MX (1) MX2007014588A (enExample)
NL (1) NL300996I2 (enExample)
PL (1) PL1889848T3 (enExample)
PT (1) PT1889848E (enExample)
RU (1) RU2403255C2 (enExample)
TW (1) TWI311056B (enExample)
WO (2) WO2006126529A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
MX347741B (es) * 2008-09-16 2017-05-10 Nektar Therapeutics Opioides pegilados con bajo potencial de abuso.
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
EP2569320A4 (en) * 2010-05-13 2014-03-19 Green Cross Corp POLYCYCLIC DERIVATIVES ON (+) - 3-HYDROXYMORPHINAN BASE AS NEUROPROTEKTIVA
AU2011327113B9 (en) * 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
JP5818219B2 (ja) * 2012-05-14 2015-11-18 塩野義製薬株式会社 ６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
JP7076171B2 (ja) * 2016-12-26 2022-05-27 塩野義製薬株式会社 含量均一性を改善した製剤の製造方法
TW202528300A (zh) 2018-04-12 2025-07-16 美商莫菲克醫療股份有限公司 人類整合素α4β7拮抗劑
KR102201609B1 (ko) * 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
BR112022007284A2 (pt) 2019-10-16 2022-07-05 Morphic Therapeutic Inc Inibição de integrina humana alpha-4 beta-7
WO2021100728A1 (ja) 2019-11-20 2021-05-27 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina
CN121534059A (zh) * 2024-08-09 2026-02-17 盐野义有限公司 一种治疗帕金森综合征或帕金森病的方法和药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) * 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) * 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) * 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
NZ268969A (en) 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
HUP9900974A3 (en) 1996-01-10 2000-09-28 Smithkline Beecham Spa Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
AU5891600A (en) 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EP1244447B1 (en) 1999-11-29 2007-01-10 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
EP1280529A2 (en) * 2000-05-05 2003-02-05 Pain Therapeutics, Inc. Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
ATE292625T1 (de) 2000-10-31 2005-04-15 Rensselaer Polytech Inst 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien
AU2408602A (en) * 2000-11-22 2002-06-03 Toray Industries Indole derivatives and use thereof in medicines
US7435817B2 (en) * 2001-08-23 2008-10-14 N.V. Organon C-14 oxidation of morphine derivatives
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
AU2003281042A1 (en) * 2002-07-11 2004-02-02 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
MXPA05002983A (es) * 2002-09-18 2005-06-22 Univ Missouri Analogos de opiato selectivos del receptor opioide d.
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
DK1758452T3 (en) 2004-05-28 2017-05-01 Human Biomolecular Res Inst METABOLIC STABLE ANALGETICS AND Painkillers
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
AU2011327113B9 (en) 2010-11-12 2015-07-30 Shionogi & Co., Ltd. Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same

Also Published As

Publication number Publication date
USRE46375E1 (en) 2017-04-25
US20120135978A1 (en) 2012-05-31
FR19C1042I2 (fr) 2020-06-19
EP1889848B1 (en) 2014-10-15
USRE46365E1 (en) 2017-04-11
TWI311056B (en) 2009-06-21
EP1889848B8 (en) 2014-12-17
BRPI0610343B1 (pt) 2020-03-10
US20090203723A1 (en) 2009-08-13
CN101228172A (zh) 2008-07-23
MX2007014588A (es) 2008-01-24
AU2006250390B2 (en) 2010-07-08
NL300996I1 (nl) 2019-07-03
BRPI0610343A2 (pt) 2010-06-15
CA2609733A1 (en) 2006-11-30
KR20080014791A (ko) 2008-02-14
RU2007148412A (ru) 2009-06-27
WO2006126637A1 (ja) 2006-11-30
AU2006250390A1 (en) 2006-11-30
PL1889848T3 (pl) 2015-04-30
PT1889848E (pt) 2014-12-09
TW200726470A (en) 2007-07-16
BE2019C533I2 (enExample) 2025-12-10
JPWO2006126637A1 (ja) 2008-12-25
KR100912782B1 (ko) 2009-08-18
BRPI0610343B8 (pt) 2021-05-25
EP1889848A4 (en) 2011-08-10
JP4323547B2 (ja) 2009-09-02
CA2609733C (en) 2011-07-19
EP1889848A1 (en) 2008-02-20
US8536192B2 (en) 2013-09-17
NL300996I2 (nl) 2019-07-30
RU2403255C2 (ru) 2010-11-10
US8084460B2 (en) 2011-12-27
CN101228172B (zh) 2013-04-03
DK1889848T3 (en) 2014-12-01
FR19C1042I1 (enExample) 2019-08-09
WO2006126529A1 (ja) 2006-11-30
HUS1900034I1 (hu) 2019-07-29

Similar Documents

Publication Publication Date Title
USRE46375E1 (en) 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
EP3820574B1 (en) 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
EP3386590B1 (en) Bicyclic inhibitors of pad4
EP3672949B1 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP2520567A2 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
US9630922B2 (en) 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
RU2475488C2 (ru) Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ
RU2485106C2 (ru) Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
CN102955359A (zh) 盐、光致抗蚀剂组合物和用于制备光致抗蚀剂图案的方法
JP2008543778A5 (enExample)
CN101420955B (zh) 可用作蛋白激酶抑制剂的二氢二氮杂*
CN101678022A (zh) 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
US20250163049A1 (en) Fused bicyclic heterocyclyl compounds as usp1 inhibitors
EP3414252B1 (en) Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
US20180360803A1 (en) Pharmaceutical composition for treatment or prevention of nash
US6765096B1 (en) Tricyclic compound having acyloxymethoxycarbonyl side chain
ES2561298T3 (es) Compuestos de aminometilquinolona
US6103732A (en) Carboxylic acid derivatives, their production and use
US12177971B2 (en) Wiring board
JP4737495B2 (ja) エリスロマイシン誘導体
EP4470533A1 (en) Novel b0at1 inhibitor
ES2447891T3 (es) Procedimiento para la preparación de beta-cetonitrilos
TH79237A (th) สารยับยั้งไกเรส และการใช้สารนี้
US20040034076A1 (en) Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists
RU2795850C2 (ru) Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения